Adma Biologics reports plans to conduct public sale of common stock

Raymond James helps finance the launch of RI-002, corporate purposes

By Devika Patel

Knoxville, Tenn., April 27 – Adma Biologics, Inc. will price a public offering of common stock with a 30-day greenshoe, according to a preliminary prospectus supplement filed Wednesday with the Securities and Exchange Commission.

Raymond James is the bookrunning manager.

Proceeds will be used for the procurement of commercial inventory and build out of a commercial organization and staffing infrastructure for the company’s planned launch of RI-002 and for general and corporate purposes.

Based in Ramsey, N.J., Adma is a late-stage biopharmaceutical company that develops, manufactures and intends to market plasma-based biologics to treat and prevent infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.